Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The increasing understanding of the role of cytokines in autoimmunity, and the observation that tumour necrosis factor alpha (TNFalpha) is central to the inflammatory and destructive process common to several human autoimmune diseases, has led to a new generation of therapeutics, the TNFalpha blocking agents. In this article, we review the current knowledge of the role of cytokines in autoimmunity as unravelled by studies both in the laboratory and the clinic. In addition, we discuss future prospects of the anti-TNFalpha therapy that may involve combination therapy with other anti-cytokine or anti-T cell biologicals, or the use of small chemicals targeting molecules involved in TNFalpha production such as NF-kappaB and p38 MAPK. The future developments of anti-TNFalpha and anti-cytokine therapy in general will be interesting.


Journal article


Cytokine growth factor rev

Publication Date





299 - 313


Animals, Anti-Inflammatory Agents, Antibodies, Monoclonal, Arthritis, Rheumatoid, Autoimmune Diseases, Autoimmunity, Clinical Trials as Topic, Cytokines, Double-Blind Method, Etanercept, Forecasting, Humans, Immunoglobulin G, Immunosuppressive Agents, Infliximab, Matrix Metalloproteinases, Mice, NF-kappa B, Receptors, Tumor Necrosis Factor, Self Tolerance, Tumor Necrosis Factor-alpha